Abstract
Background: Although it is known that Alzheimer's disease (AD) is associated with the progressive accumulation of amyloid β-peptide (Aβ) in the human brain, its pathogenic role has to be completely clarified. Aβ moves from the bloodbrain barrier to the plasma and an increased Aβ production in brain could be associated with higher Aβ concentrations in blood. A recent study has evaluated Aβ40 and Aβ42 levels in human red blood cells (RBCs) with evidence of agedependent higher Aβ concentration in RBCs.
Objective: The aim of the study was to investigate if erythrocyte associated Aβ (iAβ) levels could be different in subjects affected by dementia in comparison with controls and according to the patient’s cognitive impairment or different dementia subtypes.
Method: To answer these questions we assessed iAβ40 and iAβ42 levels in 116 patients: 32 healthy controls, 39 with diagnosis of vascular dementia (VaD), 14 mild cognitive impairment (MCI) and 31 AD.
Results: In this population we found significant differences in iAβ42 between controls and cognitive impaired patients. Moreover, iAβ42 significantly differed between dementia vs MCI. AD also showed different iAβ42 levels as compared to VaD. Conversely, no differences were found for iAβ40. All the analyses were adjusted for potential confounders like age, gender and Hb concentration. A direct correlation between increasing iAβ42 concentration and the progression of the cognitive decline using the MMSE score as continuous variable was also found.
Conclusion: Our findings support the evidence that iAβ42 could be an instrument to early recognize dementia and predict cognitive impairment.
Keywords: Alzheimer's disease, cognitive impairment, amyloid β peptide, biomarker, erythrocyte associated Aβ42, Aβ40.
Current Alzheimer Research
Title:Erythrocyte Associated Amyloid-β as Potential Biomarker to Diagnose Dementia
Volume: 15 Issue: 4
Author(s): Michele Lauriola, Giulia Paroni*, Filomena Ciccone, Grazia D`Onofrio, Leandro Cascavilla, Francesco Paris, Carolina Gravina, Maria Urbano, Davide Seripa and Antonio Greco
Affiliation:
- Complex Unit of Geriatrics, Department of Medical Sciences, I.R.C.C.S. "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo (FG),Italy
Keywords: Alzheimer's disease, cognitive impairment, amyloid β peptide, biomarker, erythrocyte associated Aβ42, Aβ40.
Abstract: Background: Although it is known that Alzheimer's disease (AD) is associated with the progressive accumulation of amyloid β-peptide (Aβ) in the human brain, its pathogenic role has to be completely clarified. Aβ moves from the bloodbrain barrier to the plasma and an increased Aβ production in brain could be associated with higher Aβ concentrations in blood. A recent study has evaluated Aβ40 and Aβ42 levels in human red blood cells (RBCs) with evidence of agedependent higher Aβ concentration in RBCs.
Objective: The aim of the study was to investigate if erythrocyte associated Aβ (iAβ) levels could be different in subjects affected by dementia in comparison with controls and according to the patient’s cognitive impairment or different dementia subtypes.
Method: To answer these questions we assessed iAβ40 and iAβ42 levels in 116 patients: 32 healthy controls, 39 with diagnosis of vascular dementia (VaD), 14 mild cognitive impairment (MCI) and 31 AD.
Results: In this population we found significant differences in iAβ42 between controls and cognitive impaired patients. Moreover, iAβ42 significantly differed between dementia vs MCI. AD also showed different iAβ42 levels as compared to VaD. Conversely, no differences were found for iAβ40. All the analyses were adjusted for potential confounders like age, gender and Hb concentration. A direct correlation between increasing iAβ42 concentration and the progression of the cognitive decline using the MMSE score as continuous variable was also found.
Conclusion: Our findings support the evidence that iAβ42 could be an instrument to early recognize dementia and predict cognitive impairment.
Export Options
About this article
Cite this article as:
Lauriola Michele , Paroni Giulia *, Ciccone Filomena , D`Onofrio Grazia, Cascavilla Leandro , Paris Francesco , Gravina Carolina , Urbano Maria , Seripa Davide and Greco Antonio , Erythrocyte Associated Amyloid-β as Potential Biomarker to Diagnose Dementia, Current Alzheimer Research 2018; 15 (4) . https://dx.doi.org/10.2174/1567205014666171110160556
DOI https://dx.doi.org/10.2174/1567205014666171110160556 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
AMPA Receptor Antagonists: Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) Current and Promising Therapies in Autosomal Recessive Ataxias
CNS & Neurological Disorders - Drug Targets NF-κB Inhibition Resolves Cognitive Deficits in Experimental Type 2 Diabetes Mellitus through CREB and Glutamate/GABA Neurotransmitters Pathway
Current Neurovascular Research Antihypertensive Therapy: Role of Aldosterone Antagonists
Current Pharmaceutical Design Vitamin D and Metabolic Syndrome: Is There a Link?
Current Pharmaceutical Design Common Cellular and Molecular Mechanisms Underlying Alzheimer’s Disease and Type 2 Diabetes: A Knowledge-Driven Approach
CNS & Neurological Disorders - Drug Targets Preface: (Commentary on the Special Issue on the Impact of Myogenic Tone in Health and Disease)
Current Vascular Pharmacology Synaptic Plasticity, Dementia and Alzheimer Disease
CNS & Neurological Disorders - Drug Targets Physical Inactivity is Liable to the Increased Cardiovascular Risk and Impaired Cognitive Profile
Current Alzheimer Research From Antioxidant Chelators to Site-Activated Multi-Target Chelators Targeting Hypoxia Inducing Factor, Beta-Amyloid, Acetylcholinesterase and Monoamine Oxidase A/B
Mini-Reviews in Medicinal Chemistry Aging in Down Syndrome and the Development of Alzheimer’s Disease Neuropathology
Current Alzheimer Research Group I Metabotropic Glutamate Receptor Interacting Proteins: Fine-Tuning Receptor Functions in Health and Disease
Current Neuropharmacology Epigenetics in the Cerebrovascular System: Changing the Code without Altering the Sequence
Current Neurovascular Research The Yin and Yang of Antiviral Innate Immunity in Central Nervous System
Current Pharmaceutical Design Neuroinflammation in Alzheimer’s Disease: Microglia, Molecular Participants and Therapeutic Choices
Current Alzheimer Research Diabetic Retinopathy and Atherosclerosis: is there a Link?
Current Diabetes Reviews The Role of Pericytes in Blood-Brain Barrier Function and Stroke
Current Pharmaceutical Design Protease-Activated Receptor 2: Are Common Functions in Glial and Immune Cells Linked to Inflammation-Related CNS Disorders?
Current Drug Targets An Effective Brain Imaging Biomarker for AD and aMCI: ALFF in Slow-5 Frequency Band
Current Alzheimer Research Berberine Nanoencapsulation Attenuates Hallmarks of Scoplomine Induced Alzheimer's-Like Disease in Rats
Current Reviews in Clinical and Experimental Pharmacology